THE RESPONSE OF URINARY 17-HYDROXYCORTICOID TO CORTICOTROPHIN ZINC AS A TEST OF ADRENAL CORTICAL FUNCTION

BY

J. S. JENKINS

From the Department of Pathology, St. Bartholomew's Hospital, London*

(RECEIVED FOR PUBLICATION APRIL 8, 1957)

An increased interest in the study of the adrenal cortex, together with the ready availability of corticotrophin (A.C.T.H.), have, in recent years, led to the development of improved methods for the assessment of adrenal cortical function. The first of such methods was devised by Thorn, Forsham, Prunty, and Hills (1948) and depended upon the fall in blood eosinophils after injection of a single dose of corticotrophin. It was subsequently realized, however, that this test was by no means specific, since a fall in eosinophils could be produced by the injection of adrenaline, for example, without any effect on the adrenal steroids (Nelson, Sandberg, Palmer, and Glenn, 1952). Moreover, there is a considerable spontaneous variation in the eosinophil count and results may be difficult to interpret when the initial count is low.

The urinary 17-ketosteroid excretion after corticotrophin provides a more valuable indication of adrenal cortical function and many of the current tests rely on this estimation. In males, however, the 17-ketosteroids are only partly derived from the adrenal cortex, and sometimes a clearly defined rise after corticotrophin is not obtained even in normal individuals. Jenkins, Forsham, Laidlaw, Reddy, and Thorn (1955) find that 14% of normal controls showed a rise of less than 2 mg. in 24 hours.

Recently, relatively simple methods have been devised for the estimation of urinary 17-hydroxycorticoids, and it seems that these methods provide a more direct measure of adrenal cortical function since the 17-hydroxycorticoids represent that fraction of the adrenal steroids known as the glucocorticoids, of which hydrocortisone and its urinary metabolites are the most important. It is now recognized that for an adequate assessment of its function a prolonged stimulation of the adrenal cortex is necessary. Jenkins et al. (1955) describe

*Permanent address: St. George's Hospital, London.
for the purification of the commercial butanol. One litre of butanol ("analar") was acidified to pH 1 with 50% sulphuric acid. One hundred milligrams of recrystallized phenylhydrazine was then added and the mixture heated to 60° C. for 30 minutes. At the end of this time the temperature was raised to boiling point and the butanol distilled at 117° C., discarding the first 50 ml. Urinary 17-hydroxycorticoids estimated by this method, using cortisone as a standard, showed in 50 individuals a normal range of 3 to 10.2 mg. per 24 hours (mean 6.3 mg.).

Urinary 17-ketosteroids were estimated by the standard method proposed by the Medical Research Council Committee on Clinical Endocrinology (1951).

Results

Normal Response to Corticotrophin. — The administration of corticotrophin zinc to 24 patients with no clinical evidence of adrenal cortical disease resulted in an unequivocal rise in urinary 17-hydroxycorticoids in every case, although there were considerable differences both in the speed and magnitude of the response. The initial control values ranged from 3 mg. to 9.3 mg., and the increase ranged from 6.6 mg. to 27.6 mg. (mean 16.1 mg.) during the day of corticotrophin and from 19.4 mg. to 59 mg. (mean 36.6 mg.) during the following day. One other normal female was not included in this series because she had been receiving small doses of corticotrophin twice weekly for several months, elsewhere, on a mistaken diagnosis of hypopituitarism. Her initial level was 8.1 mg. and after the corticotrophin test there was an enormous increase of 35.4 mg. and 90.9 mg. on the successive days. This result agrees with the findings of Forsham, di Raimondo, Island, Rinfret, and Orr (1955) that repeated small amounts of corticotrophin increase the sensitivity of the adrenal to subsequent stimulation by larger doses.

In Fig. 1 the responses of the eosinophils, the 17-ketosteroids, and the 17-hydroxycorticoids have been compared in a normal person. It will be seen that in this particular case a definite fall in eosinophils was obtained, but the rise in the 17-ketosteroid level was much less impressive than the rise in 17-hydroxycorticoids. Fig. 1 shows that even smaller doses of corticotrophin zinc cause a rise in 17-hydroxycorticoids lasting from 24 to 48 hours. The effect of oral cortisone, 12.5 mg. three times daily, is included for comparison.

Addison's Disease. — The Table and Fig. 2 show the results obtained when the test is carried out on patients suffering from Addison's disease. Three cases were studied, of which one patient, J.H., was untreated at the time of investigation. This patient showed most of the clinical features of Addison's disease, and the 17-hydroxycorticoid excretion was 2.4 mg. The administration of corticotrophin caused no rise in either the 17-hydroxycorti-
corticoid or 17-ketosteroid levels. The remaining two patients had suffered from Addison's disease for several years and were receiving treatment with oral cortisone, 12.5 mg. twice daily. This dose was sufficient to produce normal 17-hydroxycorticoid excretion under ordinary conditions, but after corticotrophin there was no significant alteration.

**Hypopituitarism.**—The use of the 17-hydroxycorticoid test in differentiating between the primary adrenal failure of Addison's disease and adrenal insufficiency secondary to hypopituitarism is shown in Fig. 2 and the Table. A male patient aged 63 suffering from hypopituitarism showed the low 17-hydroxycorticoid excretion of 1.5 mg., but this level rose to 16.5 mg. following corticotrophin. In contrast, the 17-ketosteroids rose only from 2.7 mg. to 6.6 mg. A second male patient also showed a good response, the increase in 17-hydroxycorticoids being 9.9 mg. on the day of corticotrophin and 12 mg. on the following day, although the corresponding rise in 17-ketosteroids was only 1 mg. and 1.4 mg. on these two days. A female patient with long-standing hypopituitarism following post-partum necrosis of the anterior pituitary showed a more sluggish reaction, no rise occurring on the day of corticotrophin, but a rise of 5.6 mg. was obtained on the following day. While an unequivocal increase in 17-hydroxycorticoids was obtained in all three patients using the standard test, the delayed response occurring in the third patient indicates that in cases of suspected hypopituitarism it would be wise to prolong the administration of corticotrophin for three days in order to ensure adequate stimulation.

**Cushing's Syndrome.**—The application of the test to two patients suffering from Cushing's syndrome due to bilateral adrenal cortical hyperplasia is also shown in Fig. 2 and the Table. In these cases the control 17-hydroxycorticoid values were higher than normal, and after corticotrophin a considerable response was obtained, indicating that the already hyperplastic adrenal cortex was capable of being further stimulated by exogenous corticotrophin.

**Discussion**

The results shown above indicate that the response of urinary 17-hydroxycorticoids after the administration of corticotrophin zinc differentiates between individuals with normal adrenal cortical
function and those suffering from various abnormalities of the adrenal cortex. The lack of response in Addison’s disease is contrasted with the increase obtained in hypopituitarism although this may be delayed in some patients. In the cases of Cushing’s syndrome which were investigated, the increase in 17-hydroxycorticoids after the giving of corticotrophin suggested that the patients were suffering from adrenal cortical hyperplasia rather than a malignant tumour, although laparotomy was necessary for confirmation of the diagnosis. Jenkins et al. (1955) have obtained similar results, using intravenous infusion of corticotrophin or intramuscular corticotrophin gel. These authors conclude that a rise in urinary 17-hydroxycorticoids of greater than 5 mg. per 24 hours is the best index of normal adrenal cortical response.

The injection of 40 units of corticotrophin zinc 12-hourly provides, in a convenient form, the sustained intensive stimulus required for adequate adrenal function tests and it appears that this preparation has a more prolonged action than corticotrophin gel when it is given in equivalent doses to the same patient (personal finding). Moreover, no anomalous results due to resistance to intramuscular corticotrophin necessitating intravenous infusion have so far been encountered with the zinc preparation.

Nabarro (1954), using corticotrophin gel, has suggested that there is a place for the eosinophil count and the urinary sodium/potassium ratio as screening tests before carrying out the more time-consuming urinary 17-ketosteroid estimation. The limitations of the eosinophil count have already been mentioned and the urinary sodium/potassium ratio may be affected by variations in the diet unless this is rigidly controlled. With the development of a method for the estimation of urinary 17-hydroxycorticoids which is more rapid than the 17-ketosteroid estimation and which provides a more sensitive index of adrenal cortical response, there appears to be less need for the indirect tests.

**Summary**

An increase in urinary 17-hydroxycorticoids is a sensitive index of adrenal cortical response to corticotrophin.

Patients with Addison’s disease show no increase in 17-hydroxycorticoids whereas in hypopituitarism there is a definite response.

In Cushing’s syndrome due to adrenal cortical hyperplasia there is a good response to corticotrophin.

Corticotrophin zinc provides a sustained, intensive stimulation of the adrenal cortex in a convenient form.

I would like to thank Dr. A. W. Spence and Dr. N. C. Oswald for permission to investigate patients under their care. I am indebted to Dr. A. B. Anderson and Mrs. A. M. Robinson, D.Sc., of the Department of Pathology, St. Bartholomew’s Hospital, for providing the facilities for carrying out this work and for much helpful advice. Estimations of 17-ketosteroids were carried out by Miss A. Dimoline.

**References**


**Table**

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>1st Day (Control) (mg. 24 hr.)</th>
<th>2nd Day (A.C.T.H.) (mg. Change per 24 hr.)</th>
<th>3rd Day (mg. per 24 hr.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>J.H.</td>
<td>21</td>
<td>M</td>
<td>Addison's disease (treated)</td>
<td>2.4</td>
<td>+0.2</td>
<td>-0.8</td>
</tr>
<tr>
<td>V.W.</td>
<td>18</td>
<td>M</td>
<td>Addison's disease (treated)</td>
<td>6.0</td>
<td>+1.9</td>
<td>-1.3</td>
</tr>
<tr>
<td>I.P.</td>
<td>46</td>
<td>F</td>
<td>Hypopituitarism</td>
<td>3.6</td>
<td>+1.3</td>
<td></td>
</tr>
<tr>
<td>W.P.</td>
<td>63</td>
<td>M</td>
<td></td>
<td>-1.5</td>
<td>-15.0</td>
<td></td>
</tr>
<tr>
<td>S.W.</td>
<td>59</td>
<td>M</td>
<td></td>
<td>2.4</td>
<td>+9.9</td>
<td>+12.0</td>
</tr>
<tr>
<td>J.B.</td>
<td>40</td>
<td>F</td>
<td></td>
<td>2.0</td>
<td>-1.1</td>
<td>+5.6</td>
</tr>
<tr>
<td>C.L.</td>
<td>26</td>
<td>M</td>
<td>Cushing's syndrome</td>
<td>14.3</td>
<td>+5.0</td>
<td>+36.4</td>
</tr>
<tr>
<td>P.S.</td>
<td>26</td>
<td>F</td>
<td></td>
<td>20.1</td>
<td>+8.7</td>
<td>+18.3</td>
</tr>
</tbody>
</table>

**EFFECT OF INTRAMUSCULAR TO INFUSION THAT ZINC THAT SUGGESTED W.P. V.W. 18 M 59 P.S. 26 corticotrophin gel intensive function has greater of intramuscular and Cushing's syndrome using intravenous infusion Jenkins response obtained in necessary for was from corticotrophin of increase in may 12-hourly provides,..

**EFFECT OF IN**

**CORTICOTROPHIN ON DIABETIC RESPONSE TO A.C.T.H.**
The Response of Urinary 17-Hydroxycorticoids to Corticotrophin Zinc as a Test of Adrenal Cortical Function

J. S. Jenkins

*J Clin Pathol* 1958 11: 78-81
doi: 10.1136/jcp.11.1.78

Updated information and services can be found at:
http://jcp.bmj.com/content/11/1/78.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/